# To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

> **NCT06552520** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.** · enrollment: 500 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** TQH2722 injection
- **DRUG:** Placebo of TQH2722 injection

## Key facts

- **NCT ID:** NCT06552520
- **Lead sponsor:** Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-08
- **Primary completion:** 2025-09-11
- **Final completion:** 2026-06
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06552520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06552520, "To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06552520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*